Table 2.

Time to treatment discontinuation and OS in the study population and in subgroups of interest.

	Non-ILD population (N = 10,304)	ILD population, total (N = 148)	ILD population, AI/G subgroup (n = 14)	ILD population, ‘other’ subgroup (n = 75)	ILD population, idiopathic subgroup (n = 59)
Median TTD [95% CI] (months)	2.8 [2.8–2.8]	2.5 [2.0–3.9]	1.5 [0.9–12.9]	2.5 [2.0–5.7]	2.9 [1.8–4.1]
Median OS [95% CI] (months)	11.9 [11.4–12.3]	9.6 [7.6–12.5]	8.6 [2.0–NR]	10.7 [6.7–18.7]	9.6 [6.4–19.5]
Survival at 1 year	49.7% [48.8–50.7]	40.8% [34.1–50.5]	35.7% [17.7–72.1]	43.0% [34.3–57.6]	37.3% [28.2–54.5]
Survival at 2 years	31.0% [30.1–32.0]	28.7% [22.8–38.2]	21.4% [7.9–58.4]	27.1% [19.8–41.4]	31.1% [22.7–48.5]
Survival at 3 years	22.3% [21.4–23.2]	21.1% [16.0–30.5]	14.3% [4.0–51.5]	24.0% [15.8–36.5]	20.5% [13.8–37.7]

AI/G, auto-immune or granulomatous; CI, confidence interval; ILD, interstitial lung disease; OS, overall survival.